Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Ratio: 2010-2025

Historic Equity Ratio for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to 0.51.

  • Myriad Genetics' Equity Ratio fell 24.33% to 0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.51, marking a year-over-year decrease of 24.33%. This contributed to the annual value of 0.68 for FY2024, which is 0.12% down from last year.
  • As of Q3 2025, Myriad Genetics' Equity Ratio stood at 0.51, which was down 10.64% from 0.57 recorded in Q2 2025.
  • Myriad Genetics' Equity Ratio's 5-year high stood at 0.78 during Q2 2022, with a 5-year trough of 0.51 in Q3 2025.
  • For the 3-year period, Myriad Genetics' Equity Ratio averaged around 0.65, with its median value being 0.68 (2024).
  • Per our database at Business Quant, Myriad Genetics' Equity Ratio rose by 18.01% in 2021 and then fell by 24.33% in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Equity Ratio stood at 0.73 in 2021, then increased by 0.84% to 0.74 in 2022, then decreased by 7.56% to 0.68 in 2023, then fell by 0.12% to 0.68 in 2024, then dropped by 24.33% to 0.51 in 2025.
  • Its Equity Ratio stands at 0.51 for Q3 2025, versus 0.57 for Q2 2025 and 0.70 for Q1 2025.